QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AGIO

QT64Agios Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
34.16
+1.08+3.26%
OverviewShort InterestFilings
AGIOQT64Agios Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
34.16+3.26%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-7.25
Insider Own1.81%
Shs Outstand59.47M
Perf Week18.94%
Market Cap1.97BForward P/E-EPS next Y-4.77Insider Trans0.71%Shs Float-Perf Month23.19%
Enterprise Value1.89BPEG0.03EPS next Q-1.67Inst Own-Short Float-Perf Quarter22.35%
Income-427498751.00P/S29.79EPS this Y14.07%Inst Trans-Short Ratio-Perf Half Y30.93%
Sales66.05MP/B1.75EPS next Y23.41%ROA-35.66%Short Interest-Perf YTD25.50%
Book/sh18.65P/C-EPS next 5Y-ROE-34.11%52W High46.00 -25.74%Perf Year-1.53%
Cash/sh12.39P/FCF-EPS past 3/5Y-ROIC-41.43%52W Low22.24 53.60%Perf 3Y-
Dividend Est.-EV/EBITDA-4.52Sales past 3/5Y56.83% -Gross Margin82.07%Volatility3.30% 3.25%Perf 5Y-
Dividend TTM-EV/Sales28.61EPS Y/Y TTM-162.29%Oper. Margin-719.97%ATR (14)1.47Perf 10Y-
Dividend Ex-Date-Quick Ratio13.59Sales Y/Y TTM83.33%Profit Margin-639.84%RSI (14)70.69Recom2.50
Dividend Gr. 3/5Y-Current Ratio14.19EPS Q/Q-9.03%SMA2016.49%Beta0.95Target Price43.33
Payout0.00%Debt/Eq0.03Sales Q/Q133.33%SMA5017.67%Rel Volume2.03Prev Close33.08
Employees486LT Debt/Eq0.04EarningsJul 30SMA2007.64%Avg Volume1.10MPrice34.16
IPO DateJul 24, 2013Option/ShortYes / YesEPS/Sales Surpr.6.63% 61.54%Net Debt/EBITDA0.19Volume2,241,485Change3.26%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedH.C. Wainwright$50 → $54
Apr-30-26ReiteratedTruist Financial$39 → $36
Apr-20-26ReiteratedH.C. Wainwright$62 → $50
Feb-12-26ReiteratedTruist Financial$38 → $39
Dec-26-25ReiteratedLeerink PartnersOutperform$34 → $40
Dec-24-25ReiteratedH.C. Wainwright$48 → $62
Dec-24-25ReiteratedTruist Financial$32 → $38
Nov-24-25InitiatedTruistBuy$32
Nov-20-25UpgradeLeerink PartnersMarket Perform → Outperform$56 → $34
Nov-20-25DowngradeRBC CapitalOutperform → Sector Perform
Latest News
Jun-15-26
Jun-15-2607:08PM
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event - SlideshowSeekingAlpha
03:16AM
Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response Rate And 41.1% Reduction In Transfusion Burden Versus Placebo In Sickle Cell DiseaseBenzinga
Jun-13-26
Jun-13-2602:02PM
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event TranscriptSeekingAlpha
Jun-11-26
Jun-11-2610:25AM
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue665436
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A12124
Gross Profit544332
Selling, General and Administrative Excl. Other187180157
Research and Development343334301
Other Operating Expense010
Operating Income-476-472-426
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-52-58-1,144
Net Income Before Taxes-423-414718
Income Taxes-1-144
Consolidated Net Income-422-413674
Net Income From Continuing Operations-422-413674
Net Income-422-413674
EPS (Recurring)-7.25-7.1211.86
EPS (Basic, Before Extraordinaries)-7.25-7.1211.86
EPS (Diluted)-7.25-7.1211.64
EBITDA-419-409724
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio30.5429.24—
Gross Margin81.8279.6388.89
Operating Margin-721.21-874.07-1,183.33
Net Margin-639.39-764.811,872.22
Shares Outstanding595857
Market Capitalization2,0151,579—
Operating Lease Expense
———
Insider Trading Volume
$36.67$31.36$26.05$20.73$15.42● Close Price0.00M0.33M0.66M0.99M1.32MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Owen Adams CatherineDirectorJun 13 '26Option Exercise0.003,95208,049Jun 16 12:00 AM
CAPELLO JEFFREY DDirectorJun 13 '26Option Exercise0.003,95208,049Jun 16 12:00 AM
Jones CeciliaChief Financial OfficerApr 02 '26Option Exercise0.0017,000058,139Apr 06 12:00 AM
Goff BrianChief Executive OfficerApr 02 '26Option Exercise0.0078,0560191,104Apr 06 12:00 AM
Goff BrianChief Executive OfficerApr 02 '26Sale34.7119,068661,850177,604Apr 06 12:00 AM
Gheuens SarahChief Medical OfficerApr 02 '26Option Exercise0.0017,000083,217Apr 06 12:00 AM
Gheuens SarahChief Medical OfficerApr 02 '26Sale34.712,940102,04780,277Apr 06 12:00 AM
Milanova TsvetaChief Commercial OfficerApr 02 '26Option Exercise0.0017,000050,091Apr 06 12:00 AM
Viswanadhan KrishnanChief Corp Dev & StrategyApr 02 '26Sale34.712,959102,70710,282Apr 06 12:00 AM
Burns James WilliamChief Legal OfficerApr 02 '26Option Exercise0.0017,000052,586Apr 06 12:00 AM
Viswanadhan KrishnanChief Corp Dev & StrategyApr 02 '26Option Exercise0.0016,200013,241Apr 06 12:00 AM
Jones CeciliaChief Financial OfficerApr 02 '26Sale34.713,141109,02454,998Apr 06 12:00 AM
Milanova TsvetaChief Commercial OfficerApr 02 '26Sale34.713,262113,22446,829Apr 06 12:00 AM
Burns James WilliamChief Legal OfficerApr 02 '26Sale34.713,280113,84949,306Apr 06 12:00 AM
Viswanadhan KrishnanChief Corp Dev & StrategyMar 05 '26Option Exercise0.0016,200016,200Mar 09 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR